Segment Performance
The company's non-COVID product portfolio performed well, driven by products such as Abrysvo, Eliquis, Prevnar, and the Vyndaqel family. The company's COVID-19 products saw a significant decline, with revenues decreasing by approximately 40% operationally year-over-year. Dave Denton, CFO, noted that the company's refined commercial strategy was effective, driven by these key products.
Pipeline Progress
Pfizer made significant progress in its pipeline, with 40 approvals and critical readouts, and the initiation of 11 pivotal studies. The company's obesity portfolio saw a major advancement with the VSPR three study results, demonstrating robust weight loss with its investigational next-generation injectable GLP-1 receptor agonist, PF-3944. Chris Boshoff, Chief Scientific Officer, highlighted the potential of this platform, stating that the results "provide a compelling validation of our unique proprietary ultra-long-acting peptide platform."
Valuation
Using Pfizer's current valuation metrics, we can assess what's priced in. The company's P/E Ratio is 14.92, and the Dividend Yield is 6.67%. With an ROE of 10.91%, the company is generating strong returns on equity. Analysts estimate next year's revenue growth at -3.3%, which may impact the company's valuation. However, with a robust pipeline and a strong non-COVID product portfolio, Pfizer is well-positioned for long-term growth.
Outlook
Pfizer expects total company full-year 2026 revenues to be in the range of $59.5 billion to $62.5 billion and adjusted diluted earnings per share to be in the range of $2.80 to $3.00 per share. The company is focused on investing in key assets, managing upcoming LOEs, and driving growth through its advancing R&D pipeline and business development initiatives. With a strong financial performance and a promising pipeline, Pfizer is poised for continued success.